Beyond the Pharmacy of the World: India’s ₹10,000 Crore Biopharma SHAKTI Mission Signals a New Era in Biologics

India has built a global reputation as the “Pharmacy of the World” by supplying affordable generic medicines to more than 200 countries. Today, however, the nation is preparing for its next major healthcare milestone. Through the ambitious Biopharma SHAKTI initiative, backed by a proposed ₹10,000 crore investment, India aims to accelerate its transition from manufacturing low-cost generic drugs to becoming a global powerhouse in biologics, biosimilars, and advanced therapies.

This strategic move is expected to strengthen the country’s research capabilities, expand clinical trial infrastructure, and build world-class manufacturing facilities capable of producing high-value biological medicines. The initiative reflects India’s long-term vision of competing in the rapidly growing global biopharmaceutical market.

Why the Shift from Generics to Biologics Matters

For decades, India’s pharmaceutical success has been driven by generic medicines. These drugs have improved healthcare affordability worldwide while making India one of the largest exporters of pharmaceuticals.

However, the future of medicine is increasingly focused on biologics—complex medicines developed from living cells and organisms. These therapies are transforming the treatment of diseases such as cancer, diabetes, autoimmune disorders, and rare genetic conditions. As demand for biological medicines rises globally, India is positioning itself to become a significant contributor to this high-value segment.

What is Biopharma SHAKTI?

Biopharma SHAKTI is a comprehensive government initiative designed to strengthen India’s entire biopharmaceutical ecosystem. Instead of concentrating solely on manufacturing, the programme aims to support every stage of drug development.

Its primary objectives include:

• Expanding biotechnology research and innovation.
• Building advanced clinical trial infrastructure.
• Encouraging the development of biologics and biosimilars.
• Strengthening domestic manufacturing capabilities.
• Promoting collaboration between academia, research institutions, startups, and pharmaceutical companies.

The programme is expected to create an environment where scientific discoveries can move efficiently from laboratories to commercial production.

Strengthening Research and Innovation

One of the biggest challenges in developing biologics is the need for extensive scientific research. Biological medicines require years of laboratory work, clinical validation, and regulatory approvals before reaching patients.

Biopharma SHAKTI seeks to address these challenges by encouraging investment in research centres, innovation hubs, and biotechnology collaborations. Increased funding could enable Indian scientists and pharmaceutical companies to develop breakthrough therapies while reducing dependence on imported technologies.

Building Better Clinical Trial Infrastructure

Clinical trials are essential for ensuring the safety and effectiveness of new medicines. India has a large patient population and experienced medical professionals, making it an attractive destination for clinical research.

The initiative aims to strengthen the country’s clinical trial ecosystem by improving infrastructure, enhancing regulatory efficiency, and expanding research capabilities. A stronger clinical research network will help accelerate the development of innovative biological medicines while attracting global pharmaceutical partnerships.

Expanding Advanced Manufacturing

Unlike conventional generic medicines, biologics require sophisticated manufacturing technologies and highly controlled production environments.

Biopharma SHAKTI plans to support the establishment of advanced manufacturing facilities equipped with cutting-edge biotechnology platforms. These investments will help Indian companies manufacture globally competitive biologics while meeting international quality standards.

Such capabilities could significantly enhance India’s export potential and strengthen its position in the global pharmaceutical supply chain.

Opportunities for the Indian Pharma Industry

The programme opens exciting opportunities for pharmaceutical manufacturers, biotechnology startups, research organizations, and investors.

Potential benefits include:

• Higher-value pharmaceutical exports.
• Increased investment in biotechnology.
• Growth of biosimilar manufacturing.
• More public-private research collaborations.
• Creation of highly skilled employment opportunities.
• Greater international competitiveness.

Industry experts believe the initiative could help India emerge as a leading destination for next-generation biological medicines.

Better Healthcare for Patients

The ultimate objective of Biopharma SHAKTI is not only industrial growth but also improved patient care.

As domestic production of biologics expands, patients may gain access to advanced therapies at more affordable prices. Improved availability of biological medicines can significantly improve treatment outcomes for chronic diseases, cancer, and other complex health conditions while reducing dependence on expensive imports.

Looking Ahead

India’s proposed ₹10,000 crore Biopharma SHAKTI initiative represents a defining moment in the country’s pharmaceutical journey. Having established itself as a global leader in generic medicines, India is now laying the foundation for leadership in biologics, biosimilars, and biotechnology innovation.

If implemented successfully, the initiative could transform India’s pharmaceutical ecosystem by strengthening research, modernizing clinical trials, expanding advanced manufacturing, and fostering innovation. More importantly, it positions India to play a much larger role in shaping the future of global healthcare, where biological medicines are expected to drive the next wave of medical breakthroughs.